Second Code Technologies

Orion has developed and patented a best-in-class suite of DNA methylation analysis tools advancing epigenetic research. New research shows errors in DNA methylation, DNA's Second Code, are a major contributor to age-related diseases such as cancer. Using these tools, the company is developing a new class of diagnostic products to help physicians diagnose cancer earlier and to aid in the selection of a most effective cancer therapy.

MethylScope technology is a powerful DNA methylation profiling tool, used in research laboratories to precisely map DNA methylation across entire genomes, enabling the discovery of biomarkers for disease detection and therapy selection. MethylScope technology is compatible with microarray, bead array and ultra high-throughput DNA sequencing technologies, and is positioned to be the industry standard for epigenetic research.

MethylScreen technology is a patent pending clinical assay technology. Based on the real-time PCR platform, MethylScreen assays are performed on equipment in wide use by reference laboratories in all major world markets for the cost effective measurement individual biomarkers in clinical samples.